NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

April 22, 2020

Study Completion Date

June 29, 2020

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

DS-1205c

DS-1205c 200 mg capsule for oral administration

DRUG

Gefitinib

Gefitinib 250 mg tablet for oral administration

Trial Locations (8)

Aichi Cancer Center, Chikusa

National Cancer Center Hospital East, Kashiwa

Kindai University Hospital, Sayama

The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Ariake

National Cancer Center Hospital, Tsukiji

National Hospital Organization Kyushu Cancer Center, Fukuoka

Kyushu University Hospital, Fukuoka

Shizuoka Cancer Center, Shizuoka